nach oben

Erschienen in:

09.04.2016 | Original Paper

A Randomized Controlled Trial of a Patient-Centered Approach to Improve Screening for the Metabolic Side Effects of Antipsychotic Medications

verfasst von: Julie Kreyenbuhl, Lisa B. Dixon, Clayton H. Brown, Deborah R. Medoff, Elizabeth A. Klingaman, Li Juan Fang, Stephanie Tapscott, Mary Brighid Walsh

Erschienen in: Community Mental Health Journal | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Adherence to recommendations for monitoring of metabolic side effects of antipsychotic medications has been historically low. This randomized controlled trial tested whether a computerized, patient-centered intervention that educated Veterans with serious mental illness about these side effects and encouraged them to advocate for receipt of monitoring would increase rates of monitoring compared to enhanced treatment as usual. The mean proportion of days adherent to monitoring guidelines over the 1-year study was similarly high and did not differ between the intervention (range 0.81–0.98) and comparison (range 0.76–0.96) groups. Many individuals in both groups had persistent abnormal metabolic parameter values despite high rates of monitoring, contact with medical providers, and receipt of cardiometabolic medications. Participants exposed to the intervention were interested in receiving personalized information about their cardiometabolic status, demonstrating the preliminary feasibility of brief interventions for enhancing involvement of individuals with serious mental illness in health care decision making.

Alegría, M., Carson, N., Flores, M., Li, X., Shi, P., Lessios, A. S., et al. (2014). Activation, self-management, engagement, and retention in behavioral health care: A randomized clinical trial of the DECIDE intervention. JAMA Psychiatry, 71(5), 557–565.CrossRefPubMedPubMedCentral

Allison, D. B., Newcomer, J. W., Dunn, A. L., Blumenthal, J. A., Fabricatore, A. N., Daumit, G. L., et al. (2009). Obesity among those with mental disorders: A National Institute of Mental Health meeting report. American Journal of Preventive Medicine, 36(4), 341–350.CrossRefPubMed

American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27(2), 596–601.CrossRef

Angst, F., Stassen, H. H., Clayton, P. J., & Angst, J. (2002). Mortality of patients with mood disorders: Follow-up over 34-38 years. Journal of Affective Disorders, 68(2–3), 167–181.CrossRefPubMed

Barnes, T. R., Paton, C., Hancock, E., Cavanagh, M. R., Taylor, D., Lelliott, P., & UK Prescribing Observatory for Mental Health. (2008). Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: A quality improvement programme. Acta Psychiatrica Scandinavica, 118(1), 26–33.CrossRefPubMed

Bartels, S. J., Aschbrenner, K. A., Rolin, S. A., Hendrick, D. C., Naslund, J. A., & Faber, M. J. (2013). Activating older adults with serious mental illness for collaborative primary care visits. Psychiatric Rehabilitation Journal, 36(4), 278–288.CrossRefPubMedPubMedCentral

Brown, S., Birtwistle, J., Roe, L., & Thompson, C. (1999). The unhealthy lifestyle of people with schizophrenia. Psychological Medicine, 29(3), 697–701.CrossRefPubMed

Brown, S., Inskip, H., & Barraclough, B. (2000). Causes of the excess mortality of schizophrenia. British Journal of Psychiatry, 177, 212–217.CrossRefPubMed

Colton, C. W., & Manderscheid, R. W. (2006). Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Preventing Chronic Disease, 3(2), A42.PubMedPubMedCentral

DelMonte, M. T., Bostwick, J. R., Bess, J. D., & Dalack, G. W. (2012). Evaluation of a computer-based intervention to enhance metabolic monitoring in psychiatry inpatients treated with second-generation antipsychotics. Journal of Clinical Pharmacy and Therapeutics, 37(6), 668–673.CrossRefPubMed

Dixon, L., Medoff, D., Wohlheiter, K., DiClemente, C., Goldberg, R., Kreyenbuhl, J., et al. (2007). Correlates of severity of smoking among persons with severe mental illness. American Journal on Addictions, 16(2), 101–110.CrossRefPubMed

Dixon, L., Weiden, P., Delahanty, J., Goldberg, R., Postrado, L., Lucksted, A., & Lehman, A. (2000). Prevalence and correlates of diabetes in national schizophrenia samples. Schizophrenia Bulletin, 26(4), 903–912.CrossRefPubMed

Eisen, S. V., Normand, S., Belanger, A. J., Spiro, A., & Esch, D. (2004). The Revised Behavior and Symptom Identification Scale (BASIS-R): Reliability and validity. Medical Care, 42(12), 1230–1241.CrossRefPubMed

Giguère, A., Légaré, F., Grimshaw, J., Turcotte, S., Fiander, M., Grudniewicz, A., et al. (2012). Printed educational materials: Effects on professional practice and healthcare outcomes. The Cochrane Database of Systematic Reviews, 10, CD004398.PubMed

Heppner, P. S., Lohr, J. B., Kash, T. P., Jin, H., Wang, H., & Baker, D. G. (2012). Metabolic syndrome: Relative risk associated with post-traumatic stress disorder (PTSD) severity and antipsychotic medication use. Psychosomatics, 53(6), 550–558.CrossRefPubMed

Huber, P. J. (1967). The behavior of maximum likelihood estimates under nonstandard conditions. In L. M. Le Cam & J. Neyman (Eds.), Proceedings of the fifth Berkeley symposium on mathematical statistics and probability (Vol. 1). Berkeley: University of California Press.

Institute of Medicine. (2001). Crossing the Quality Chasm: A new health system for the 21st century. Washington, DC: National Academy Press.

Kilbourne, A. M., Morden, N. E., Austin, K., Ilgen, M., McCarthy, J. F., Dalack, G., & Blow, F. C. (2009). Excess heart-disease-related mortality in a national study of patients with mental disorders: Identifying modifiable risk factors. General Hospital Psychiatry, 31(6), 555–563.CrossRefPubMedPubMedCentral

Liang, K.-Y., & Zeger, S. L. (1993). Regression analysis for correlated data. Annual Review of Public Health, 14, 43–68.CrossRefPubMed

Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353(12), 1209–1223.CrossRefPubMed

Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Casey, D. E., Davis, J. M., et al. (2004). Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry, 161(8), 1334–1349.CrossRefPubMed

McEvoy, J. P., Meyer, J. M., Goff, D. C., Nasrallah, H. A., Davis, S. M., Sullivan, L., et al. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research, 80(1), 19–32.CrossRefPubMed

Mead, N., & Bower, P. (2000). Patient-centeredness: A conceptual framework and review of the empirical literature. Social Science and Medicine, 51(7), 1087–1110.CrossRefPubMed

Mitchell, A. J., Delaffon, V., Vancampfort, D., Correll, C. U., & De Hert, M. (2012). Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: Systematic review and meta-analysis of screening practices. Psychological Medicine, 42(1), 125–147.CrossRefPubMed

Mitchell, A. J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W., & De Hert, M. (2013). Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—A systematic review and meta-analysis. Schizophrenia Bulletin, 39(2), 306–318.CrossRefPubMed

Mittal, D., Li, C., Williams, J. S., Viverito, K., Landes, R. D., & Owen, R. R. (2013). Monitoring veterans for metabolic side effects when prescribing antipsychotics. Psychiatric Services, 64(1), 28–35.CrossRefPubMed

Morden, N. E., Lai, Z., Goodrich, D. E., MacKenzie, T., McCarthy, J. F., Austin, K., et al. (2012). Eight-year trends of cardiometabolic morbidity and mortality in patients with schizophrenia. General Hospital Psychiatry, 34(4), 368–379.CrossRefPubMedPubMedCentral

New Freedom Commission on Mental Health. (2003). Achieving the promise: Transforming Mental Health Care in America. Final report. DHHS Publication No. SMA-03-3832, Rockville, MD.

Newcomer, J. W. (2007). Metabolic considerations in the use of antipsychotic medications: A review of recent evidence. Journal of Clinical Psychiatry, 68(Suppl 1), 20–27.PubMed

Nicol, G. E., Morrato, E. H., Johnson, M. C., Campagna, E., Yingling, M. D., Pham, V., & Newcomer, J. W. (2011). Best practices: Implementation of a glucose screening program based on diffusion of innovation theory methods. Psychiatric Services, 62(1), 12–14.CrossRefPubMed

Osby, U., Correia, N., Brandt, L., Ekbom, A., & Sparén, P. (2000). Mortality and causes of death in schizophrenia in Stockholm County. Sweden. Schizophrenia Research, 45(1–2), 21–28.CrossRefPubMed

Ramanuj, P. P. (2013). Improving blood and ECG monitoring among patients prescribed regular antipsychotic medications. Mental Health in Family Medicine, 10(1), 29–36.PubMedPubMedCentral

Rethorst, C. D., Bernstein, I., & Trivedi, M. H. (2014). Inflammation, obesity, and metabolic syndrome in depression: Analysis of the 2009–2010 National Health and Nutrition Examination Survey (NHANES). Journal of Clinical Psychiatry, 75(12), e1428–e1432.CrossRefPubMedPubMedCentral

Rotondi, A. J., Eack, S. M., Hanusa, B. H., Spring, M. B., & Haas, G. L. (2015). Critical design elements of e-health applications for users with severe mental illness: singular focus, simple architecture, prominent contents, explicit navigation, and inclusive hyperlinks. Schizophrenia Bulletin, 41(2), 440–448.CrossRefPubMed

Rummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., et al. (2010). Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis. Schizophrenia Research, 123(2–3), 225–233.CrossRefPubMedPubMedCentral

Saha, S., Chant, D., & McGrath, J. (2007). A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time? Archives of General Psychiatry, 64(10), 1123–1131.CrossRefPubMed

Schneiderhan, M. E., Batscha, C. L., & Rosen, C. (2009). Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents. Pharmacotherapy, 29(8), 975–987.CrossRefPubMed

Schulz, K. F., Altman, D. G., Moher, D., & CONSORT Group. (2010). CONSORT 2010 statement: Updated guidelines for reporting parallel group randomized trials. Annals of Internal Medicine, 152(11), 726–732.CrossRefPubMed

Stewart, M. A. (1995). Effective physician–patient communication and health outcomes: A review. CMAJ. Canadian Medical Association Journal, 152(9), 1423–1433.PubMedPubMedCentral

Stewart, M., Brown, J. B., Donner, A., McWhinney, I. R., Oates, J., Weston, W. W., & Jordan, J. (2000). The impact of patient-centered care on patient outcomes. Journal of Family Practice, 49(9), 796–804.PubMed

Stewart, M., Brown, J. B., Weston, W. W., McWhinney, I. R., McWilliam, C. L., & Freeman, C. R. (2014). Patient-centered medicine: Transforming the clinical method (3rd ed.). London: Radcliffe Publishing Ltd.

Thompson, A., Hetrick, S. E., Alvarez-Jiménez, M., Parker, A. G., Willet, M., Hughes, F., et al. (2011). Targeted intervention to improve monitoring of antipsychotic-induced weight gain and metabolic disturbance in first episode psychosis. The Australian and New Zealand Journal of Psychiatry, 45(9), 740–748.CrossRefPubMed

Velligan, D. I., Castillo, D., Lopez, L., Manaugh, B., Davis, C., Rodriguez, J., et al. (2013). A case control study of the implementation of change model versus passive dissemination of practice guidelines for compliance in monitoring for metabolic syndrome. Community Mental Health Journal, 49(2), 141–149.CrossRefPubMed

Titel: A Randomized Controlled Trial of a Patient-Centered Approach to Improve Screening for the Metabolic Side Effects of Antipsychotic Medications
verfasst von: Julie Kreyenbuhl
Lisa B. Dixon
Clayton H. Brown
Deborah R. Medoff
Elizabeth A. Klingaman
Li Juan Fang
Stephanie Tapscott
Mary Brighid Walsh
Publikationsdatum: 09.04.2016
Verlag: Springer US
Erschienen in: Community Mental Health Journal / Ausgabe 2/2017
Print ISSN: 0010-3853
Elektronische ISSN: 1573-2789
DOI: https://doi.org/10.1007/s10597-016-0007-5

Neu im Fachgebiet Psychiatrie

23.04.2024 | Demenz | Nachrichten

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

A Randomized Controlled Trial of a Patient-Centered Approach to Improve Screening for the Metabolic Side Effects of Antipsychotic Medications

Abstract

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Psychiatrie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Cognitive Behavioral Therapy for Psychosis (CBT-p) Delivered in a Community Mental Health Setting: A Case Comparison of Clients Receiving CBT Informed Strategies by Case Managers Prior to Therapy

Three-Dimensional Model of Strengths: Examination of Invariance Across Gender, Age, Education Levels, and Marriage Status

Cognitive Behavioral Therapy Compared with Non-specialized Therapy for Alleviating the Effect of Auditory Hallucinations in People with Reoccurring Schizophrenia: A Systematic Review and Meta-analysis

Peer Models in Mental Health for Caregivers and Families

Attitudes of Primary Care Health Workers Towards Mental Health Patients: A Cross-Sectional Study in Osun State, Nigeria

Is Telemental Health Services a Viable Alternative to Traditional Psychotherapy for Deaf Individuals?

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Psychiatrie